Company news
Curatis Holding Ag (SIX:CURN) news
Curatis Holding Ag news releases on 6ix. Latest, Sep 21, 2026: Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress…
Press releases & updates
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)
September 21, 2026
Curatis Increases Revenue Growth Guidance for 2026
June 11, 2026
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
May 22, 2026
Curatis Holding AG announces CHF 3.0 million private placement with strategic investor
May 22, 2026
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved
March 24, 2026
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
March 11, 2026
Curatis Holding AG announces CHF 1.2 million private placement with strategic investor
November 21, 2025
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3
September 18, 2025
Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01
September 15, 2025
Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues
September 5, 2025
Curatis discloses Corticorelin as active substance of C-PTBE-01
May 23, 2025
Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01
March 27, 2025
Curatis Announces Formation of Distinguished Advisory Board
March 11, 2025